We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+7.42%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$14.1B
AUM Growth
+$2.17B
(+18%)
Cap. Flow
+$1.47B
Cap. Flow
% of AUM
10.47%
Top 10 Holdings %
Top 10 Hldgs %
18.97%
Holding
1,309
New
346
Increased
287
Reduced
265
Closed
392
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoetis
ZTS
|
+$177M |
| 2 |
Lowe's Companies
LOW
|
+$108M |
| 3 |
STJ
St Jude Medical
STJ
|
+$95.4M |
| 4 |
Newell Brands
NWL
|
+$88.6M |
| 5 |
Constellation Brands
STZ
|
+$87.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EMC
EMC CORPORATION
EMC
|
+$136M |
| 2 |
UnitedHealth
UNH
|
+$99.3M |
| 3 |
PayPal
PYPL
|
+$85.4M |
| 4 |
Starbucks
SBUX
|
+$78.1M |
| 5 |
Cigna
CI
|
+$64.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.63% |
| 2 | Consumer Discretionary | 12.48% |
| 3 | Communication Services | 12.09% |
| 4 | Technology | 9.72% |
| 5 | Industrials | 9.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
376
Starbucks
SBUX
$118B
| $5.98M | 0.04% |
110,423
-1,396,684
| -93% | -$78.1M |
|
|
CLVS
377
DELISTED
Clovis Oncology, Inc.
CLVS
| $5.97M | 0.04% |
+165,737
| New | +$3.56M |
|
378
CVS Health
CVS
$137B
| $5.97M | 0.04% |
67,105
-341,766
| -84% | -$32.3M |
|
|
WWE
379
DELISTED
World Wrestling Entertainment
WWE
| $5.92M | 0.04% |
278,004
+140,182
| +102% | +$2.83M |
|
|
VSTO
380
DELISTED
Vista Outdoor Inc.
VSTO
| $5.91M | 0.04% |
148,236
+107,517
| +264% | +$4.75M |
|
381
Dycom Industries
DY
$12.9B
| $5.9M | 0.04% |
72,165
+62,665
| +660% | +$5.53M |
|
382
Oneok
OKE
$58.7B
| $5.86M | 0.04% |
+113,977
| New | +$5.39M |
|
383
Zurn Elkay Water Solutions
ZWS
$8.07B
| $5.85M | 0.04% |
567,304
-861,727
| -60% | -$8.74M |
|
|
IMPV
384
DELISTED
Imperva, Inc.
IMPV
| $5.75M | 0.04% |
+107,046
| New | +$4.97M |
|
385
Agios Pharmaceuticals
AGIO
$2.16B
| $5.67M | 0.04% |
+107,423
| New | +$4.68M |
|
386
Akebia Therapeutics
AKBA
$327M
| $5.63M | 0.04% |
621,850
+160,333
| +35% | +$1.36M |
|
387
Regal Rexnord
RRX
$14.2B
| $5.57M | 0.04% |
93,703
-64,828
| -41% | -$3.9M |
|
|
NSA
388
DELISTED
National Storage Affiliates Trust
NSA
| $5.51M | 0.04% |
263,311
-106,379
| -29% | -$2.23M |
|
|
BNY
389
Bank of New York Mellon
BNY
$108B
| $5.49M | 0.04% |
137,679
-113,590
| -45% | -$4.54M |
|
|
BWLD
390
DELISTED
Buffalo Wild Wings, Inc.
BWLD
| $5.48M | 0.04% |
+38,913
| New | +$6.05M |
|
391
Healthcare Services Group
HCSG
$1.56B
| $5.45M | 0.04% |
+137,661
| New | +$5.4M |
|
392
AES
AES
$10.6B
| $5.4M | 0.04% |
+420,400
| New | +$5.24M |
|
|
WMGI
393
DELISTED
Wright Medical Group Inc
WMGI
| $5.39M | 0.04% |
219,882
-809,983
| -79% | -$18.7M |
|
|
ESV
394
DELISTED
Ensco Rowan plc
ESV
| $5.34M | 0.04% |
156,983
+130,555
| +494% | +$4.44M |
|
395
Macy's
M
$6.15B
| $5.32M | 0.04% |
+143,653
| New | +$5.21M |
|
396
AGCO
AGCO
$8.78B
| $5.31M | 0.04% |
107,670
-74,566
| -41% | -$3.58M |
|
397
MSCI
MSCI
$40B
| $5.3M | 0.04% |
63,184
-542,557
| -90% | -$46.1M |
|
398
Lam Research
LRCX
$382B
| $5.29M | 0.04% |
558,130
-543,830
| -49% | -$4.95M |
|
|
KA
399
DELISTED
Kineta, Inc. Common Stock
KA
| $5.22M | 0.04% |
+2,393
| New | +$4.45M |
|
|
PACEU
400
DELISTED
Pace Holdings Corp.
PACEU
| $5.2M | 0.04% |
500,000
| – | – |
|
Similar funds
Marshall Wace's Q3 2016 Portfolio in Review
As of Q3 2016, Marshall Wace held 1,309 positions worth $14.1B, up 18% from $11.9B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Marshall Wace deployed $1.47B of net new capital in Q3 2016, opening 346 new positions and adding to 287 existing holdings. Its largest new stake was St Jude Medical: 1,181,595 shares worth $94.2M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was UnitedHealth, an estimated $99.3M trimmed.
- Marshall Wace's largest Q3 2016 buy was St Jude Medical: 1,181,595 shares worth $94.2M.
- Marshall Wace added most to Zoetis in Q3 2016, an estimated $177M increase.
- Marshall Wace's biggest Q3 2016 reduction was UnitedHealth, cutting an estimated $99.3M.
- Marshall Wace fully exited EMC CORPORATION in Q3 2016, selling an estimated $136M.
- Marshall Wace's ten largest holdings make up 19% of its $14.1B portfolio in Q3 2016.
- Marshall Wace opened 346 new positions and closed 392 in Q3 2016.
- Marshall Wace's portfolio value rose 18% quarter-over-quarter to $14.1B.
Based on Marshall Wace's 13F filing for Q3 2016, filed 10 Nov 2016.